Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS
Date:8/6/2013

DUBLIN, Aug. 6, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter ended June 30, 2013 and updated 2013 financial guidance.

"During the second quarter, we continued our track record of delivering strong top and bottom line growth fueled by increasing sales of Xyrem® and Erwinaze®," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "We remain committed to creating long-term shareholder value through disciplined investments to support expansion in our research and development, commercial and operational capacities and pursuit of promising corporate development opportunities."

Adjusted net income for the second quarter of 2013 was $88.3 million, or $1.43 per diluted share, compared to $66.2 million, or $1.09 per diluted share, for the second quarter of 2012. 

GAAP net income for the second quarter of 2013 was $42.2 million, or $0.69 per diluted share.  GAAP income from continuing operations for the second quarter of 2012 was $31.1 million, or $0.51 per diluted share, and GAAP net income for the second quarter of 2012 was $27.1 million, or $0.45 per diluted share.  GAAP net income for the second quarter of 2012 included GAAP loss from discontinued operations of $4.0 million, or $0.06 per diluted share.Reconciliations of applicable GAAP to non-GAAP adjusted information are included with this press release.

Second Quarter 2013 Revenues and Product SalesTotal revenues for the second quarter of 2013 were $208.3 million, compared to total revenues of $124.2 million for the second quarter of 2012.  The increase in total revenues for the quarter ended June 30, 2013 was driven primarily by increased net sales of Xyrem and the inclusion of Erwinaze product sales for the full reporting period in 2013.

Total revenues for the quarter ended June 30, 2013 included net sales, royalties and contract revenues.  Tables showing net sales for the three and six months ended June 30, 2013 compared to actual and pro forma net sales for the same periods in 2012 are included in this press release.

Net sales for the second quarter of 2013 were as follows:

  • Xyrem® (sodium oxybate) oral solution:  Xyrem net sales increased by 50% to $133.7 million in the second quarter of 2013 compared to $89.1 million in the second quarter of 2012.  During the second quarter of 2013, the average number of active Xyrem patients was approximately 10,700.
  • Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi):  Erwinaze/ Erwinase worldwide net sales increased to $44.9 million in the second quarter of 2013 compared to pro forma net sales of $32.9 million in the second quarter of 2012, or an increase of 36% on a pro forma basis.  Erwinaze/Erwinase pro forma net sales represent net product sales as if the acquisition of EUSA Pharma had been completed on January 1, 2012.
  • Prialt® (ziconotide) intrathecal infusion:  Net sales of Prialt were $4.7 million in the second quarter of 2013 compared to net sales of $5.6 million for the same period of 2012.  During the second quarter of 2013, net sales were impacted by the transition to an exclusive specialty pharmacy, which is accessed through our Navigator Reimbursement and Access Program™ for Prialt.
  • Psychiatry Products:  Net sales of the company's psychiatry products were $11.8 million in the second quarter of 2013 compared to net sales of $19.8 million for the same period of 2012.  Second quarter 2013 net sales of the psychiatry products were impacted by continued generic competition.
  • Other:  Net sales of other products for the second quarter of 2013 were $11.5 million compared to pro forma net sales of $12.4 million in the same period of 2012.  "Other" includes products acquired in the EUSA Pharma and Azur Pharma transactions that are not mentioned above. 
  • Operating Expenses and Other Operating expenses for the second quarter of 2013 increased to $131.2 million compared to $84.8 million for the second quarter of 2012.  Operating expenses increased over the prior year period for the following reasons:

  • Cost of product sales for the second quarter of 2013 was $25.0 million compared to $12.3 million for the same period in 2012.  The increase in the 2013 period was primarily due to higher net sales and a change in product mix. Gross margin for the second quarter of 2013, as a percentage of product sales, was 87.9% compared to 90.0% for the same period in 2012.  Our gross margin percentage in the second quarter of 2013 as compared to the same period in 2012 was lower primarily due to lower gross margins on products acquired as part of the EUSA Pharma acquisition.
  • Selling, general and administrative ("SG&A") and research and development ("R&D") expenses for the second quarter of 2013 totaled $86.8 million on a GAAP basis compared to $59.5 million for the same period of 2012.  The increase reflected higher headcount and related expenses due primarily to the expansion of our business and an increase in the fair value of contingent consideration related to the EUSA Pharma acquisition, partially offset by lower transaction and integration costs.  Adjusted SG&A and R&D expenses for the second quarter of 2013 totaled $70.6 million compared to $44.0 million for the same period in 2012.
  • Intangible asset amortization for the second quarter of 2013 was $19.4 million compared to $13.0 million for the same period in 2012.  The increase was primarily related to amortization of intangible assets acquired as part of the EUSA Pharma acquisition.
  • Second quarter of 2013 net interest expense was $7.1 million, and the loss on extinguishment and modification of debt was $3.7 million.  As of June 30, 2013, our cash and cash equivalents were $504.3 million, and the balance of our term loans was $552.3 million. The balance of cash and cash equivalents increased from December 31, 2012 primarily due to the cash generated from our business and the net proceeds of the new term loans, offset in part by funds used to repurchase our ordinary shares under our share repurchase program and increases in working capital.

    In May 2013, our board of directors authorized the use of up to $200 million to repurchase the company's ordinary shares.  As of June 30, 2013, we had repurchased 846,197 shares for $53.6 million at an average cost of $63.32 per share. 

    On June 13, 2013, we amended our credit agreement, increased the principal amount of the term loans to $557.2 million, an increase of $100 million from the remaining principal amount of the original term loans, and increased the revolving credit facility from $100 million to $200 million.  The interest rate on our term loans is currently 3.5% based on a 0.75% LIBOR floor plus a margin of 2.75% per annum, compared to an interest rate of 5.25% prior to the amended credit agreement. Our revolving credit facility remains undrawn.

    During the fourth quarter of 2012, the company sold its women's health business.  Financial results from the women's health business are reported as discontinued operations for the 2012 periods.

    2013 Financial Guidance Jazz Pharmaceuticals is providing the following updated 2013 guidance:Revenues

     

    $860-$880 million

     Total Net Product Sales

     

    $853-$873 million

     -Xyrem Net Sales

    -Erwinaze/Erwinase Net Sales

    $560-$570 million

    $170-$180 millionAdjusted Gross Margin %1,3

    88-90% Adjusted Combined SG&A and R&D Expenses2,3

     

    $280-$290 million  

    GAAP Net Income Per Diluted Share

    $3.26-$3.55Adjusted Net Income Per Diluted Share3

    $6.20-$6.40


    1. Excludes $4 million of acquisition accounting inventory fair value step-up and $3 million in share-based compensation expense from estimated GAAP gross margin of 87-89%.
    2. Excludes $42-$44 million of share-based compensation expense, $15 million related to a change in fair value of contingent consideration, $3 million of depreciation expense, $4 million of upfront license fees and $3 million of transaction, integration and restructuring costs from estimated GAAP combined SG&A and R&D expenses of $347-$359 million.
    3. See "Non‑GAAP Financial Measures" below.  Reconciliations of non-GAAP adjusted guidance measures are included above and elsewhere in this press release.

    Other Announcements

  • We received Fast Track designation for Asparec (mPEG-r-crisantaspase) from the U.S. Food and Drug Administration ("FDA") for the treatment of acute lymphoblastic leukemia.
  • We continue our efforts to strengthen and broaden our intellectual property related to Xyrem.  Two new patents issued in June 2013.  Thirteen U.S. patents have now been issued related to Xyrem's stable and microbially resistant formulation, its manufacturing process and its method of use, including its restricted distribution system.
  • In August 2013, we received a close-out letter from the FDA with respect to the October 2011 warning letter regarding certain aspects of our adverse event reporting system for Xyrem and drug safety procedures. 
  • For Prialt, we expanded our collaboration with Medtronic—the market leader in intrathecal pumps.  The partnership now includes a sales force collaboration that is focused on targeted activities at the field level.
  • Conference Call DetailsJazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EDT (9:30 p.m. IST) to provide a business update and discuss its second quarter 2013 results and updated 2013 financial guidance.  The live webcast may be accessed from the Investors & Media section of the company's website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary.  Investors may participate in the conference call by dialing +1 877 280 4953 in the U.S., or +1 857 244 7310 outside the U.S., and entering passcode 10594339.

    A replay of the conference call will be available through August 13, 2013 by dialing +1 888 286 8010 in the U.S., or +1 617 801 6888 outside the U.S., and entering passcode 72340817.

    An archived version of the webcast will be available for at least one week in the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.

    About Jazz PharmaceuticalsJazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs.  The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.  The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion and FazaClo® (clozapine, USP) HD.  Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com.

    Non-GAAP Financial MeasuresTo supplement Jazz Pharmaceuticals' financial results and guidance presented on a GAAP basis, the company uses certain non-GAAP adjusted financial measures.  The company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results, particularly in light of the effect of various acquisition and divestiture transactions effected by the company during 2012.  They are not meant to be considered in isolation or as a substitute for comparable GAAP measures, and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP.  Jazz Pharmaceuticals' management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate its business and make operating decisions.  Compensation of executives is based in part on the performance of the company's business based on certain of these non-GAAP measures.  In addition, Jazz Pharmaceuticals believes that the use of these non-GAAP measures enhances the ability of investors to compare its results from period to period.  The non-GAAP adjusted financial measures as used by Jazz Pharmaceuticals in this press release may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the company's competitors and other companies.

    As used in this press release, (i) the historical adjusted net income measures exclude from GAAP income from continuing operations, as applicable, amortization of intangible assets, share-based compensation expense, acquisition accounting inventory fair value step-up adjustments, transaction and integration costs, restructuring charges, change in fair value of contingent consideration, upfront license fees, depreciation expense, loss on extinguishment and modification of debt and other non-cash expense, and adjust the income tax provision to the estimated amount of taxes that are payable in cash; (ii) the historical adjusted combined SG&A and R&D expenses exclude from GAAP combined SG&A and R&D expenses, as applicable, share-based compensation expense, change in fair value of contingent consideration, transaction, integration and restructuring costs, depreciation expense and upfront license fees; (iii) the adjusted net income guidance measures exclude from estimated GAAP net income amortization of intangible assets and depreciation expense, share-based compensation expense, acquisition accounting inventory fair value step-up adjustments, transaction, integration and restructuring costs, change in fair value of contingent consideration, upfront license fees, loss on extinguishment and modification of debt and other non-cash expense, and adjust the income tax provision to the estimated amount of taxes that are payable in cash; (iv) the adjusted gross margin percentage guidance excludes from estimated GAAP gross margin percentage acquisition accounting inventory fair value step-up and share-based compensation expense; and (v) the adjusted combined SG&A and R&D expenses guidance excludes from estimated GAAP combined SG&A and R&D expenses share-based compensation expense, change in fair value of contingent consideration, depreciation expense, upfront license fees and transaction, integration and restructuring costs.

    "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial results and growth potential, including 2013 financial guidance, plans to pursue investment and corporate development opportunities, efforts to strengthen and broaden intellectual property protection and other statements that are not historical facts.  These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining and increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition and changed or increased regulatory restrictions on or requirements with respect to Xyrem, as well as similar risks related to effectively commercializing the company's other marketed products, including Erwinaze and Prialt; protecting and expanding the company's intellectual property rights; obtaining appropriate pricing and reimbursement for the company's products in an increasingly challenging environment; ongoing regulation and oversight by U.S. and non-U.S. regulatory agencies; dependence on key customers and sole source suppliers, including the risk that the company may not be able to timely resolve potential product supply shortages and meet product demand; the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval; the company's ability to identify and acquire, in-license or develop additional products or product candidates to grow its business; and possible restrictions on the company's ability and flexibility to pursue certain future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results; and those other risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and future filings and reports by the company.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.JAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share amounts)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,2013201220132012Revenues:Product sales, net

    $
    206,564$
    23,002$
    401,216$
    224,454Royalties and contract revenues

    1,6881,2293,2732,307Total revenues

    208,252124,231404,489226,761Operating expenses:Cost of product sales

    25,03112,28952,25120,033Selling, general and administrative

    77,50657,224148,034101,580Research and development

    9,2502,32119,9976,280Intangible asset amortization

    19,39912,97038,95423,702Total operating expenses

    131,18684,804259,236151,595Income from operations

    77,06639,427145,25375,166Interest expense, net

    (7,142)(1,481)(14,541)(1,450)Foreign currency loss

    (385)(240)(114)(258)Loss on extinguishment and modification of debt

    (3,749)-(3,749)-Income from continuing operations before income  tax provision

    65,79037,706126,84973,458Income tax provision

    23,6056,59341,23912,110Income from continuing operations

    42,18531,11385,61061,348Loss from discontinued operations

    -(3,968)-(6,522)Net income 

    $
    42,185$
    27,145$
    85,610$
    54,826Basic income (loss) per ordinary share:Income from continuing operations

    $
    .72$
    .55$
    .46$
    .11Loss from discontinued operations

    -(0.07)-(0.12)Net income

    $
    .72$
    .48$
    .46$
    .99Diluted income (loss) per ordinary share:Income from continuing operations

    $
    .69$
    .51$
    .39$
    .03Loss from discontinued operations

    -(0.06)-(0.11)Net income

    $
    .69$
    .45$
    .39$
    .92Weighted-average ordinary shares used inper share computations:Basic

    58,73756,95258,54855,437Diluted

    61,56860,55461,54159,319 JAZZ PHARMACEUTICALS PLCSUMMARY OF PRODUCT SALES, NET(In thousands)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,2013201220132012Xyrem

    $
    33,742$
    89,097$
    251,268$
    2,534Erwinaze/Erwinase

    44,8606,00786,6766,007Prialt

    4,6945,5559,68015,077Psychiatry

    11,76419,78929,41437,487Other

    11,5042,55424,1783,349Total

    $
    206,564$
    23,002$
    401,216$
    224,454The following compares actual net product sales for the three and six months ended June 30, 2013 to unaudited pro forma information representing combined net product sales for the three and six months ended June 30, 2012, as if the merger with Azur Pharma, the acquisition of EUSA Pharma and the disposition of the women's health business had each been completed on January 1, 2012: SUMMARY OF PRODUCT SALES, NET (PRO FORMA)  (In thousands)  (Unaudited) Three Months EndedSix Months EndedJune 30,June 30,2013201220132012Xyrem

    $
    33,742$
    89,097$
    251,268$
    2,534Erwinaze/Erwinase

    44,86032,88886,67665,795Prialt 

    4,6945,5559,68015,417Psychiatry

    11,76419,78929,41437,849Other

    11,50412,41624,17825,290Total pro forma net sales

    $
    206,564$
    59,745$
    401,216$
    306,885 JAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands) (Unaudited) June 30,December 31,20132012ASSETSCurrent assets:Cash and cash equivalents

    $
    504,307$
    387,196Accounts receivable, net

    114,07575,480Inventories

    28,13026,525Prepaid expenses

    21,4107,445Deferred tax assets, net

    46,53835,813Other current assets

    19,71619,113Total current assets

    734,176551,572Property and equipment, net

    10,7687,281Intangible assets, net

    822,976869,952Goodwill

    439,014442,600Deferred tax assets, net, non-current

    65,13674,850Deferred financing costs

    16,30816,576Other long-term assets

    5,5023,662Total assets

    $   2,093,880$
    ,966,493LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities:Accounts payable

    $
    20,367$
    5,887Accrued liabilities

    96,771104,666Current portion of long-term debt 

    5,57229,688Income taxes payable

    17,53939,884Contingent consideration

    42,700-Deferred tax liability, net

    259275Deferred revenue

    1,1381,138Total current liabilities

    184,346191,538Deferred revenue, non-current

    6,2836,776Long-term debt, less current portion 

    546,724427,073Contingent consideration, non-current

    -34,800Deferred tax liability, net, non-current

    167,744178,393Other non-current liabilities

    13,3306,621Total shareholders' equity 

    1,175,4531,121,292Total liabilities and shareholders' equity 

    $   2,093,880$
    ,966,493JAZZ PHARMACEUTICALS PLCRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(In thousands, except per share amounts)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,2013201220132012GAAP income from continuing operations

    $
    42,185$
    31,113$
    85,610$
    ,348Intangible asset amortization

    19,39912,97038,95423,702Share-based compensation expense

    11,5065,04820,2638,329Acquisition accounting inventory fair value step-up

    1,0863,0322,6314,340Transaction and integration costs

    71110,0941,73316,189Restructuring charges

    5085471,457547Change in fair value of contingent consideration

    3,4002007,900200Upfront license fees

    --4,000-Depreciation

    595-1,170-Loss on extinguishment and modification of debt

    3,749-3,749-Other non-cash expense 

    1,1932672,422309Income tax adjustments

    3,9772,8972,8452,897Adjusted net income

    $
    88,309$
    ,168$
    72,734$
    7,861GAAP income from continuing operations per diluted share

    $
    .69$
    .51$
    .39$
    .03Adjusted net income per diluted share

    $
    .43$
    .09$
    2.81$
    .99Shares used in computing GAAP income from continuing continuing operations and adjusted net incomeper diluted share amounts

    61,56860,55461,54159,319 JAZZ PHARMACEUTICALS PLC  RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION  CERTAIN LINE ITEMS AND OTHER INFORMATION  (In thousands, except per share amounts and percentages)  (Unaudited) Three Months EndedJune 30, 2013June 30, 2012GAAPAdjustmentNon-GAAPGAAPAdjustmentNon-GAAPTotal revenues

    $
    208,252$
    -$   208,252$
    24,231$
    -$
    24,231Cost of product sales

    25,031(1,633)

    (a)

    23,39812,289(3,326)

    (i)

    8,963Selling, general and administrative

    77,506(14,620)

    (b)

    62,88657,224(15,073)

    (j)

    42,151Research and development

    9,250(1,553)

    (c)

    7,6972,321(522)

    (k)

    1,799Intangible asset amortization

    19,399(19,399)-12,970(12,970)-Interest expense, net

    7,142(1,193)

    (d)

    5,9491,481(267)

    (l)

    1,214Foreign currency loss

    385-385240-240Loss on extinguishment and modification of debt

    3,749(3,749)----Income from continuing operationsbefore income tax provision

    65,79042,147

    (e)

    107,93737,70632,158

    (e)

    69,864Income tax provision

    23,605(3,977)

    (f)

    19,6286,593(2,897)

    (m)

    3,696
    Effective tax rate (g)

    35.9%18.2%17.5%5.3%Income from continuing operations

    42,18546,124

    (h)

    88,30931,11335,055

    (n)

    66,168Income from continuing operations per diluted share

    $
    .69$
    .43$
    .51$
    .09(a)

    Acquisition accounting inventory fair value step-up of $1,086, share-based compensation expense of $488, transaction and integration costs of $33 and restructuring charges of $26.(b)

    Share-based compensation expense of $9,539, change in fair value of contingent consideration of $3,400, transaction and integration costs of $623, depreciation expense of $576 and restructuring charges of $482.(c)

    Share-based compensation expense of $1,479, transaction and integration costs of $55 and depreciation expense of $19.(d)

    Non-cash interest expense associated with debt discount and debt issuance costs.(e)

    Sum of the above adjustments.(f)

    Adjustments to convert the income tax provision to the estimated amount of taxes payable in cash.(g)

    Income tax provision divided by income from continuing operations before income tax provision.(h)

    Net of adjustments (e) and (f).(i)

    Acquisition accounting inventory fair value step-up of $3,032 and share-based compensation expense of $294.(j)

    Transaction and integration costs of $10,094, share-based compensation expense of $4,232, restructuring expense of $547 and change in fair value of contingent consideration of $200.(k)

    Share-based compensation expense.(l)

    Non-cash interest expense associated with debt discount and debt issuance costs and amortization of product rights liability.(m)

    Tax related to acquisition restructuring of $5,850 partially offset by adjustments of $2,953 to convert the income tax provision to the estimated amount of taxes payable in cash.(n)

    Net of adjustments (e) and (m). JAZZ PHARMACEUTICALS PLC  RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION  CERTAIN LINE ITEMS AND OTHER INFORMATION  (In thousands, except per share amounts and percentages)  (Unaudited) Six Months EndedJune 30, 2013June 30, 2012GAAPAdjustmentNon-GAAPGAAPAdjustmentNon-GAAPTotal revenues

    $
    404,489$
    -$   404,489$
    226,761$
    -$
    226,761Cost of product sales

    52,251(3,929)

    (a)

    48,32220,033(4,995)

    (i)

    15,038Selling, general and administrative

    148,034(28,608)

    (b)

    119,426101,580(23,573)

    (j)

    78,007Research and development

    19,997(6,617)

    (c)

    13,3806,280(1,037)

    (k)

    5,243Intangible asset amortization

    38,954(38,954)-23,702(23,702)-Interest expense, net

    14,541(2,422)

    (d)

    12,1191,450(309)

    (l)

    1,141Foreign currency loss

    114-114258-258Loss on extinguishment and modification of debt

    3,749(3,749)----Income from continuing operationsbefore income tax provision

    126,84984,279

    (e)

    211,12873,45853,616

    (e)

    127,074Income tax provision 

    41,239(2,845)

    (f)

    38,39412,110(2,897)

    (m)

    9,213
    Effective tax rate (g)

    32.5%18.2%16.5%7.3%Income from continuing operations

    85,61087,124

    (h)

    172,73461,34856,513

    (n)

    117,861Income from continuing operations per diluted share

    $
    .39$
    2.81$
    .03$
    .99(a)

    Acquisition accounting inventory fair value step-up of $2,631, share-based compensation expense of $1,197, restructuring charges of $68 and transaction and integration costs of $33.(b)

    Share-based compensation expense of $16,544, change in fair value of contingent consideration of $7,900, transaction and integration costs of $1,645, restructuring charges of $1,389 and depreciation expense of $1,130.(c)

    Upfront license fees of $4,000, share-based compensation expense of $2,522, transaction and integration costs of $55 and depreciation expense of $40.(d)

    Non-cash interest expense associated with debt discount and debt issuance costs.(e)

    Sum of the above adjustments.(f)

    Adjustments to convert the income tax provision to the estimated amount of taxes payable in cash.(g)

    Income tax provision divided by income from continuing operations before income tax provision.(h)

    Net of adjustments (e) and (f).(i)

    Acquisition accounting inventory fair value step-up of $4,340 and share-based compensation expense of $655.(j)

    Transaction and integration costs of $16,189, share-based compensation expense of $6,637, restructuring charges of $547 and change in fair value of contingent consideration of $200.(k)

    Share-based compensation expense.(l)

    Non-cash interest expense associated with debt discount and debt issuance costs and amortization of product rights liability.(m)

    Tax related to acquisition restructuring of $5,850 partially offset by adjustments of $2,953 to convert the income tax provision to the estimated amount of taxes payable in cash.(n)

    Net of adjustments (e) and (m).  JAZZ PHARMACEUTICALS PLC  RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2013 FINANCIAL GUIDANCE  (In millions, except per share amounts)  (Unaudited)  GAAP net income 

    $200 - $218 Intangible asset amortization and depreciation 

    82-84 Share-based compensation expense 

    45-47 Acquisition accounting inventory fair value step-up 

    4 Transaction, integration and restructuring costs 

    3 Change in fair value of contingent consideration 

    15 Upfront license fees 

    4 Loss on extinguishment and modification of debt 

    4 Other non-cash expense 

    5 Income tax adjustments 

    13-15 Adjusted net income 

    $381 - $393 GAAP net income per diluted share 

    $3.26 - $3.55 Adjusted net income per diluted share 

    $6.20 - $6.40 Shares used in computing GAAP and adjusted  net income per diluted share amounts 

    61 


    '/>"/>
    SOURCE Jazz Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
    2. Inovio Pharmaceuticals Responds to Market Activity
    3. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    4. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
    5. Avanir Pharmaceuticals to Participate in Two Conferences in August
    6. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    7. AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
    8. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
    9. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
    10. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
    11. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
    (Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
    (Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
    Breaking Medicine Technology:
    (Date:5/5/2016)... ... 2016 , ... The U.S. Food and Drug Administration today ... submit their products through an arduous federal approval process. The rules, which treat ... market since February 15, 2007. That would essentially ban 99 percent of all ...
    (Date:5/5/2016)... ... , ... This weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from ... Team Semper Fi Mountain Bike Camp, hosted in conjunction with WTB and ... and Jason Moeschler, who’ll share pro tips with the injured veterans as they rip down ...
    (Date:5/5/2016)... ... May 05, 2016 , ... LELO has discovered many people ... fans reach out via email, social media and on the Volonté blog seeking advice ... way I masturbate ‘normal’ or ‘correct’?” , While some methods are more common than ...
    (Date:5/5/2016)... ... May 05, 2016 , ... ... in all U.S. states and certain Canadian provinces is now available from the ... Research Institute (WCRI). , The report, Workers’ Compensation Laws as of ...
    (Date:5/5/2016)... ... 05, 2016 , ... Long Island’s fastest growing comprehensive eye care provider, ... surgeon, Kathleen Van Valkenburg, MD as part of their ongoing effort to increase ophthalmic ... and managing partner of North Shore Eye Care. , “We are extremely proud ...
    Breaking Medicine News(10 mins):